Osteoporosis

Merck Discontinues Development of its Osteoporosis Candidate due to Stroke Risk

KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that it is discontinuing the development of odanacatib, Merck’s investigational cathepsin K inhibitor for osteoporosis, and will not seek regulatory approval for its use. Merck previously reported a numeric imbalance in adjudicated stroke events in …

Read More »

Amgen Announces Positive Top-Line Results from Late-Stage Prolia Study

THOUSAND OAKS, Calif., Aug. 29, 2016 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced positive top-line results from the primary analysis conducted in a Phase 3 randomized, double-blind, double-dummy, active-controlled study evaluating the safety and efficacy of Prolia® (denosumab) compared with risedronate in patients receiving glucocorticoid treatment. The study met all …

Read More »

Fewer Older Women with Hip Fractures Receive Osteoporosis Care

WASHINGTON, July 18, 2016 /PRNewswire-USNewswire/ — Fewer than 1 in 5 older women who break their hip have at least one of the recommended osteoporosis screening tests or treatments within six months, according to a new AARP Public Policy Institute (PPI) study. Women ages 80 and older who break a …

Read More »

Amgen, UCB Osteoporosis Drug Succeeds in Late-Stage Trial

THOUSAND OAKS, Calif. and BRUSSELS, Feb. 22, 2016 /PRNewswire/ — Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced top-line results from the Phase 3 placebo-controlled FRActure study in postmenopausal woMen with ostEoporosis (FRAME). These data showed FRAME met the co-primary endpoints by reducing the incidence of new vertebral fracture through …

Read More »

Amgen Reacquires Rights to Three Drugs from GSK

THOUSAND OAKS, Calif., Dec. 14, 2015 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that it has entered into a definitive agreement with GSK to reacquire all of its remaining rights to Prolia® (denosumab), XGEVA®(denosumab) and Vectibix® (panitumumab) in 48 countries in Asia, South America, Europe, Australia and other regions throughout the world. …

Read More »